newsfilter
← Earnings
Earnings Releases·

MapLight Therapeutics — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Cash, cash equivalents, and investments totaled $463.4 million as of September 30, 2026, compared to $453.1 million as of December 31, 2025.
    • Research and development (R&D) expenses were $44.2 million for the quarter ended September 30, 2026, an increase from $27.1 million in the same period in 2025.
    • General and administrative (G&A) expenses were $11.1 million for the quarter ended September 30, 2026, an increase from $4.4 million in the same period in 2025.
    • Net loss was $51.6 million for the quarter ended September 30, 2026, compared to a net loss of $29.4 million in the same period in 2025.
    • Total operating expenses for the quarter were $55.3 million, up from $31.5 million in the prior year period.
    • Interest income was $3.1 million for the quarter ended September 30, 2026, compared to $1.5 million in the same period in 2025.
    • Net loss per share (basic and diluted) was $0.97 for the quarter ended September 30, 2026, compared to $37.18 in the same period in 2025.
    • Weighted-average common shares outstanding were 53.1 million for the quarter ended September 30, 2026, compared to 0.8 million in the same period in 2025.
    • Total assets were $477.2 million as of September 30, 2026, compared to $479.5 million as of December 31, 2025.
    • Total liabilities were $31.4 million as of September 30, 2026, compared to $21.1 million as of December 31, 2025.
    • Total stockholders' equity was $445.8 million as of September 30, 2026, compared to $458.4 million as of December 31, 2025.
  • Guidance and Future Outlook:

    • The Company expects its current cash position to fund operations through key clinical readouts and through 2028.
    • Topline results for the ZEPHYR-2 Phase 3 trial of ML-007C-MA in schizophrenia are expected in the second half of 2027.
    • Topline results for the VISTA Phase 2 trial of ML-007C-MA in Alzheimer's disease psychosis (ADP) are now expected in 2028.
    • The Company plans to engage with the FDA at an End-of-Phase 2 meeting to discuss the registrational path for ML-007C-MA and ML-004.
    • Following the FDA meeting for ML-004, the Company intends to evaluate development options, including potential strategic collaborations and funding alternatives.
  • Business Segments and Product Lines:

    • ML-007C-MA (Schizophrenia): The Phase 2 ZEPHYR trial met its primary endpoint, showing a statistically significant reduction in PANSS total score at Week 5 for the 210/3 mg twice-daily dose. The drug demonstrated improvement on a prespecified cognitive-function endpoint and separation on secondary endpoints including CGI-S and PANSS Marder positive factor. It was generally well-tolerated with no serious or drug-related severe adverse events and low GI-related discontinuation rates.
    • ML-007C-MA (Alzheimer's Disease Psychosis): The drug holds FDA Fast Track designation for ADP. Enrollment is ongoing in the Phase 2 VISTA trial involving approximately 300 participants.
    • ML-004 (Autism Spectrum Disorder): The Phase 2 IRIS trial demonstrated clinically meaningful improvements in a pre-specified secondary irritability endpoint among adolescents with moderate or greater baseline irritability. The drug was well-tolerated with no severe or serious adverse events in the active treatment arm.
    • The Company is pausing significant further investment in preclinical and discovery-stage programs beyond near-term milestones and is foregoing advancement of those programs into clinical development under the current operating plan.
  • Market and Competitive Landscape:

    • ML-007C-MA is positioned to compete in the broader antipsychotic market.
    • The clinical profile of ML-007C-MA, characterized by simple initiation, 99% of patients reaching the target dose, and no fasting requirement, is designed to translate into real-world use.
    • The Company notes that ML-007C-MA offers potential for meaningful differentiation in the Alzheimer's disease psychosis market.
    • ML-004 addresses a treatment setting with limited approved options, where antipsychotic-associated safety and tolerability concerns can present challenges for long-term use in younger patients.
  • Risks and Challenges:

    • Forward-looking statements regarding clinical development, trial timing, regulatory approvals, and funding sufficiency are subject to risks and uncertainties, including the unpredictable relationship between preclinical and clinical results.
    • Actual results may differ materially from expectations due to risks such as the timing or likelihood of regulatory filings, the possibility that trial results may not be indicative of future outcomes, and other risks identified in the Company's SEC filings.
  • Management Commentary and Tone:

    • CEO Chris Kroeger stated that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for the planned Phase 3 trial.
    • Management expressed confidence in the potential of ML-007C-MA in schizophrenia and sees a compelling opportunity in Alzheimer's disease psychosis.
    • The Company stated it is well-positioned to advance both programs while maintaining strategic and financial flexibility.
  • Other Key Points:

    • The Company completed a $150 million private placement in August 2026 with participation from new and existing institutional investors.
    • Proceeds from the August 2026 financing are expected to primarily support the advancement of ML-007C-MA (including the ZEPHYR-2 and VISTA trials), working capital, and other general corporate purposes.
    • ML-007C-MA received FDA Fast Track designation for ADP in December 2025.
    • The Company is planning start-up activities for the ZEPHYR-2 confirmatory Phase 3 trial of ML-007C-MA in schizophrenia.
Company
MAPLIGHT THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology